Sugi Predict

Sugi Predict / Compounds / Hydrazine

Hydrazine

Hydrazine

SCHEMBL2231845

C[C@@H](C(=O)O)N(C)C.NN

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.40
▸ SLC7A5 Q01650 2/20 0.39
▸ GABRR1 P24046 2/20 0.35
▸ CHRNB2 P17787 1/20 0.32
▸ CHRNB4 P30926 1/20 0.32
▸ CHRNA3 P32297 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32
▸ SLC1A3 P43003 2/20 0.31
▸ SLC1A2 P43004 2/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ SLC1A1 P43005 1/20 0.31
▸ ENPEP Q07075 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrazine SCHEMBL2231840 1.00 TP53 (0.40) TP53SLC7A5GABRR1CHRNB2CHRNB4
SCHEMBL754117 0.94 — —
SCHEMBL27445506 0.94 TP53 (0.44) TP53SLC7A5GABRR1
SCHEMBL50989 0.94 — —
SCHEMBL50988 0.94 — —
SCHEMBL14889907 0.94 TP53 (0.44) TP53SLC7A5GABRR1
Urea SCHEMBL2222199 0.92 TP53 (0.38) TP53SLC7A5GABRR1CHRNB2CHRNB4
Urea SCHEMBL2033880 0.92 TP53 (0.38) TP53SLC7A5GABRR1CHRNB2CHRNB4
Water SCHEMBL439514 0.91 — —
Water SCHEMBL439515 0.91 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097097-B1 ANTIBODIES, IN PARTICULAR HUMAN ANTIBODIES, THAT BIND CD22 AND USES THEREOF SQUIBB & SONS LLC (US) 2018-05-30 — — EP disclosed
US-20170058031-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF SQUIBB & SONS LLC (US) 2017-03-02 — — US disclosed
US-9499632-B2 Human antibodies that bind CD22 and uses thereof E.R. SQUIBB & SONS, L.L.C. (US) 2016-11-22 — — US disclosed
EP-1747021-B1 SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES SQUIBB & SONS LLC (US) 2015-09-09 — — EP disclosed
US-20130230530-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF MEDAREX, INC. (US) 2013-09-05 — — US disclosed
US-8481683-B2 Human antibodies that bind CD22 and uses thereof MEDAREX, INC. (US) 2013-07-09 — — US disclosed
US-8461117-B2 Chemical linkers and cleavable substrates and conjugates thereof MEDAREX, INC. (US) 2013-06-11 — — US disclosed
US-8399403-B2 drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors MEDAREX, INC. (US) 2013-03-19 — — US disclosed
EP-2354163-A2 Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies Medarex, Inc. (US) 2011-08-10 — — EP disclosed
US-20100150950-A1 HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF MEDAREX, INC. (US) 2010-06-17 — — US disclosed
WO-2009054863-A2 HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOF MEDAREX, INC. (US) 2009-04-30 — — WO disclosed
US-20080279868-A1 Antibody-Drug Conjugates and Methods of Use MEDAREX, INC. (US) 2008-11-13 — — US disclosed
WO-2008083312-A2 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF MEDAREX, INC. (US) 2008-07-10 — — WO disclosed
EP-1940470-A2 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE Medarex Inc. (US) 2008-07-09 — — EP disclosed
WO-2008074004-A2 HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF MEDAREX, INC. (US) 2008-06-19 — — WO disclosed
WO-2008070569-A2 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF MEDAREX, INC. (US) 2008-06-12 — — WO disclosed
WO-2007038658-A2 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE MEDAREX, INC. (US) 2007-04-05 — — WO disclosed
EP-1747021-A2 SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES Medarex, Inc. (US) 2007-01-31 — — EP disclosed
US-20060024317-A1 drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors MEDAREX, INC (US) 2006-02-02 — — US disclosed
WO-2005112919-A2 SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES MEDAREX, INC. (US) 2005-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060024317-A1 drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors CD74, HSP90B1, LY96 TP53 7/4885SLC7A5 610/4885GABRR1 2892/4885
US-20170058031-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF CD2BP2, CD22, CD2 TP53 989/4885SLC7A5 3000/4885GABRR1 3971/4885
US-20130230530-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF CD2BP2, CD22, CD2 TP53 989/4885SLC7A5 3000/4885GABRR1 3971/4885
US-20100150950-A1 HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF CD2BP2, CD74, CD63 TP53 194/4885SLC7A5 1253/4885GABRR1 3098/4885
US-20080279868-A1 Antibody-Drug Conjugates and Methods of Use CD47, ANTXR2, CD2BP2 TP53 166/4885SLC7A5 1450/4885GABRR1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.